MX2023014347A - Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos. - Google Patents
Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos.Info
- Publication number
- MX2023014347A MX2023014347A MX2023014347A MX2023014347A MX2023014347A MX 2023014347 A MX2023014347 A MX 2023014347A MX 2023014347 A MX2023014347 A MX 2023014347A MX 2023014347 A MX2023014347 A MX 2023014347A MX 2023014347 A MX2023014347 A MX 2023014347A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrrolo
- substituted phenyl
- pyridine derivatives
- useful
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021097679 | 2021-06-01 | ||
| CN2022085680 | 2022-04-08 | ||
| PCT/CN2022/095901 WO2022253167A1 (en) | 2021-06-01 | 2022-05-30 | SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014347A true MX2023014347A (es) | 2023-12-13 |
Family
ID=82016507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014347A MX2023014347A (es) | 2021-06-01 | 2022-05-30 | Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230250096A1 (https=) |
| EP (1) | EP4347588A1 (https=) |
| JP (1) | JP2024521879A (https=) |
| KR (1) | KR20240016324A (https=) |
| CN (1) | CN117396476A (https=) |
| AR (1) | AR126011A1 (https=) |
| AU (1) | AU2022286467A1 (https=) |
| CA (1) | CA3218479A1 (https=) |
| CL (1) | CL2023003531A1 (https=) |
| CO (1) | CO2023016217A2 (https=) |
| CR (1) | CR20230605A (https=) |
| DO (1) | DOP2023000250A (https=) |
| EC (1) | ECSP23095641A (https=) |
| IL (1) | IL308862A (https=) |
| MX (1) | MX2023014347A (https=) |
| PE (1) | PE20242359A1 (https=) |
| TW (1) | TW202313606A (https=) |
| UY (1) | UY39795A (https=) |
| WO (1) | WO2022253167A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| US20250197392A1 (en) | 2022-04-08 | 2025-06-19 | Janssen Pharmaceutica Nv | Crystalline forms of an inhibitor of the menin/mll interaction |
| EP4626426A1 (en) * | 2022-11-30 | 2025-10-08 | JANSSEN Pharmaceutica NV | Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent |
| WO2024114666A1 (en) * | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor |
| AR132185A1 (es) * | 2023-03-24 | 2025-06-04 | Acerta Pharma Bv | COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA |
| WO2025119184A1 (zh) * | 2023-12-04 | 2025-06-12 | 首药控股(北京)股份有限公司 | 取代的多环化合物 |
| WO2026062248A1 (en) * | 2024-09-20 | 2026-03-26 | Acerta Pharma B.V. | Solid-state forms of ((s)-2-(3-(1-(5,5-dimethylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-2-methyl-1h-pyrrolo[2,3-c]-pyridin-1-yl)-5-fluoro-n,n-diisopropylbenzamide salts |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102984941B (zh) | 2009-09-04 | 2016-08-17 | 密执安大学评议会 | 用于治疗白血病的组合物和方法 |
| US8927550B2 (en) | 2009-10-27 | 2015-01-06 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as CCR1 receptor antagonists |
| GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| IN2014DN01883A (https=) | 2011-09-14 | 2015-05-15 | Proximagen Ltd | |
| WO2014164543A1 (en) | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US20160113893A1 (en) | 2013-06-12 | 2016-04-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| HK1246593A1 (zh) | 2015-06-04 | 2018-09-14 | Kura Oncology, Inc. | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 |
| AU2016378579A1 (en) | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| US10869868B2 (en) | 2016-01-26 | 2020-12-22 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| PL3429591T3 (pl) | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| JP6991585B2 (ja) | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| WO2017214367A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| AU2017326006B2 (en) * | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018109088A1 (en) | 2016-12-15 | 2018-06-21 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-mll interaction |
| CN108456208B (zh) | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
| WO2018175746A1 (en) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
| WO2018226976A1 (en) | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| EP3684361A4 (en) | 2017-09-20 | 2021-09-08 | Kura Oncology, Inc. | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING |
| JP2022503792A (ja) | 2018-09-26 | 2022-01-12 | クラ オンコロジー，インク． | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| JP7618567B2 (ja) | 2019-09-27 | 2025-01-21 | 住友ファーマ株式会社 | 架橋型光学活性２級アミン誘導体 |
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
-
2022
- 2022-05-30 IL IL308862A patent/IL308862A/en unknown
- 2022-05-30 CN CN202280039035.9A patent/CN117396476A/zh active Pending
- 2022-05-30 KR KR1020237044791A patent/KR20240016324A/ko active Pending
- 2022-05-30 US US18/015,661 patent/US20230250096A1/en active Pending
- 2022-05-30 MX MX2023014347A patent/MX2023014347A/es unknown
- 2022-05-30 WO PCT/CN2022/095901 patent/WO2022253167A1/en not_active Ceased
- 2022-05-30 PE PE2023003148A patent/PE20242359A1/es unknown
- 2022-05-30 CR CR20230605A patent/CR20230605A/es unknown
- 2022-05-30 AU AU2022286467A patent/AU2022286467A1/en active Pending
- 2022-05-30 CA CA3218479A patent/CA3218479A1/en active Pending
- 2022-05-30 JP JP2023574163A patent/JP2024521879A/ja active Pending
- 2022-05-30 EP EP22729029.3A patent/EP4347588A1/en active Pending
- 2022-05-31 AR ARP220101437A patent/AR126011A1/es unknown
- 2022-05-31 TW TW111120214A patent/TW202313606A/zh unknown
- 2022-06-01 UY UY0001039795A patent/UY39795A/es unknown
-
2023
- 2023-11-14 DO DO2023000250A patent/DOP2023000250A/es unknown
- 2023-11-27 CL CL2023003531A patent/CL2023003531A1/es unknown
- 2023-11-29 CO CONC2023/0016217A patent/CO2023016217A2/es unknown
- 2023-12-28 EC ECSENADI202395641A patent/ECSP23095641A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2023000250A (es) | 2024-04-30 |
| ECSP23095641A (es) | 2024-01-31 |
| AR126011A1 (es) | 2023-08-30 |
| PE20242359A1 (es) | 2024-12-16 |
| IL308862A (en) | 2024-01-01 |
| CO2023016217A2 (es) | 2023-12-11 |
| CN117396476A (zh) | 2024-01-12 |
| EP4347588A1 (en) | 2024-04-10 |
| TW202313606A (zh) | 2023-04-01 |
| CA3218479A1 (en) | 2022-12-08 |
| WO2022253167A1 (en) | 2022-12-08 |
| UY39795A (es) | 2022-11-30 |
| CL2023003531A1 (es) | 2024-06-14 |
| JP2024521879A (ja) | 2024-06-04 |
| AU2022286467A1 (en) | 2024-01-25 |
| US20230250096A1 (en) | 2023-08-10 |
| WO2022253167A8 (en) | 2023-03-09 |
| CR20230605A (es) | 2024-05-24 |
| KR20240016324A (ko) | 2024-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014347A (es) | Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos. | |
| JOP20220154A1 (ar) | مشتقات سبيرو بسلسلة مستقيمة بها استبدال | |
| MX2023013174A (es) | Derivados espiro sustituidos. | |
| MX389598B (es) | Inhibidores bicíclicos condensados de la interacción de menina-mll. | |
| ZA202408030B (en) | Tricyclic heterocyclic derivatives, compositions and uses thereof | |
| TW200700093A (en) | Pharmaceutical composition for the treatment of cancer | |
| PL373414A1 (en) | 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands | |
| MX392051B (es) | Inhibidores espirobiciclicos de la interaccion de menina-mll | |
| MX2020006594A (es) | Inhibidores de exo-azaespiro de la interaccion menina-mll. | |
| BR112023023463A2 (pt) | Inibidores da interação menin-mll | |
| WO2022262796A8 (en) | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| BR112023021040A2 (pt) | Derivados espiro substituídos | |
| MX2025012818A (es) | Derivados de heterociclicos triciclicos, composiciones y usos de estos | |
| DE69113221D1 (en) | Antiatherosclerotische und antithrombotische 2-amino-6-phenyl-4h-pyran-4-one. | |
| NZ524936A (en) | Methods of inducing cancer cell death and tumor regression using a FTP inhibitor and a tyrosine kinase inhibitor | |
| MX2025012133A (es) | Derivados de tiadiazolona, composiciones y usos de estos | |
| SE0300457D0 (sv) | Novel compounds | |
| MX391405B (es) | Inhibidores de azepano de la interacción menina-mll. | |
| MX2022006179A (es) | Derivados macrociclicos de indol como inhibidores de mcl-1. | |
| BR112023025436A2 (pt) | Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas | |
| MX2022006180A (es) | Derivados macrociclicos de sulfonilo como inhibidores de mcl-1. | |
| BRPI0519023A2 (pt) | composiÇço farmacÊutica contendo pelo menos um derivado de dolastatina 10 | |
| ECSP055700A (es) | Uso de derivados de 4-piridil-metil-ftalazina para la fabricación de un medicamento para el tratamiento de síndromes mielodisplásticos | |
| UY27944A1 (es) | Terapia de combinacinn para enfermedades hiperproliferativas |